Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Multiple Micronutrient Supplements

The Global Shift from Iron-Folate Alone

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

20 human trials, about 6 studies, Large LMIC trials + Cochrane reviews. The written rationale for this grade is still being prepared.

FDA
Combination supplements; WHO guidance evolving for low-income settings
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

MMS is broadly safe in pregnancy, and the debate is mainly a public-health and cost question for low- and middle-income settings rather than a reason for a well-nourished person to megadose. Benefits are clearest in populations with widespread deficiency; where diets are already adequate, the incremental gain over good food plus targeted supplements is smaller. Formulations vary, and more nutrients is not automatically safer or better, some ingredients such as vitamin A and iron have upper limits that matter in pregnancy. Anyone weighing a prenatal, whether iron-folic acid, a UNIMMAP-style supplement, or a premium branded product, should decide with an obstetric provider or midwife who can match it to individual needs and local guidance rather than treating a longer ingredient list as inherently superior.

In wealthy countries a daily multivitamin prenatal is taken for granted, but across much of the world the antenatal standard has long been iron and folic acid alone. The global question is whether to switch to multiple micronutrient supplements, usually 15 vitamins and minerals in the UNIMMAP formulation. Large trials and the 2019 Cochrane review in low- and middle-income countries found MMS reduced low birthweight and small-for-gestational-age births compared with iron-folic acid, and a 2025 pooled analysis found the sharpest gains among the frailest newborns. On that evidence WHO moved from advising against MMS to backing it in the context of rigorous research, and major funders and several governments have begun the transition. The gains are clearest where deficiency is widespread, which is a different situation from a well-nourished person choosing among premium prenatal brands.

In much of the world the prenatal question is not which boutique formula, but whether to give multiple micronutrients at all instead of just iron and folic acid.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Reducing low birthweight and small-for-gestational-age births versus iron-folic acid in deficient populations
  • Lowering the risk of the frailest newborn types, preterm combined with small-for-gestational-age and low birthweight
  • Broadening micronutrient coverage where diets are limited and multiple deficiencies coexist
  • Replacing iron-folic-acid-only antenatal programs at population scale where facility births and skilled care are available
  • Improving concentrations of selected nutrients in breast milk and maternal blood during lactation

What people get wrong

  • Often saidEveryone has always taken a full multivitamin prenatal.

    ActuallyFor decades the antenatal standard across much of the world has been iron and folic acid alone. The multi-nutrient UNIMMAP formulation was only agreed in 1999, and WHO did not move toward recommending it until 2020, so the global shift to multiple micronutrients is recent (Tuncalp and colleagues, BMJ Global Health 2020).

  • Often saidMore micronutrients in a prenatal is always better.

    ActuallyMMS clearly helps in deficient populations, cutting low birthweight by about 12 percent versus iron-folic acid in the 2019 Cochrane review, but in well-nourished ones the added benefit over diet plus targeted supplements is smaller. The aim is filling real gaps, not maximizing the ingredient list.

  • Often saidMMS with less iron than iron-folic acid raises the risk of newborn death.

    ActuallyThis concern was a main reason WHO kept its recommendation conditional. A 2022 reanalysis by iron dose (Gomes and colleagues, Public Health Nutrition) found no significant difference in neonatal mortality between MMS and iron-folic acid once iron doses were compared like for like; the earlier signal came from trials that gave MMS less iron than the control arm.

Who profits, and who pushes back

  • Cochrane / large LMIC trials

    championsMMS vs iron-folic acid

    Multiple micronutrient supplementation reduced low-birth-weight and small-for-gestational-age births compared with iron-folic acid alone in low- and middle-income settings.

  • World Health Organization

    endorsesEvolving antenatal guidance

    WHO has moved toward cautious support for MMS in the context of rigorous research and where it can replace iron-folic acid, reflecting the accumulating trial evidence.

  • MMS lactation research

    endorsesBreast-milk quality studies

    Postpartum, MMS improved breast-milk quality, increasing milk omega-3s and several vitamins and raising maternal blood levels of DHA, vitamin D, folate, and B12.

  • Well-nourished-population caveat

    caveatsHigh-income context

    The clearest benefits are in deficient populations; in well-nourished settings the incremental value over a good diet plus targeted supplements is smaller, and maximalism is not the goal.

Where the research comes from

Most of the published research on this comes from one place. 55% of it is from MMS adopting. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

Share of published research by country of origin.
PlaceShare of published research
MMS adopting55%
IFA only45%

Research published from: Global.

How we got here

Iron and folic acid became the antenatal standard because they address the two most consequential and widespread problems in pregnancy: anemia, tracked for centuries across South Asia, sub-Saharan Africa, and Latin America, and neural tube defects. The idea of a broader antenatal mix was formalized in 1999, when UNICEF, WHO, and the United Nations University agreed on UNIMMAP, the United Nations International Multiple Micronutrient Antenatal Preparation, 15 nutrients at roughly one recommended daily allowance each. Field trials followed through the 2000s and 2010s across Bangladesh, Nepal, Indonesia, Niger, Burkina Faso, China, and elsewhere. As those trials accumulated and were pooled, the picture sharpened: broader supplementation further reduced low birthweight and growth restriction beyond iron-folic acid. WHO guidance shifted from advising against MMS to conditional support in 2020, and the largest implementation research has since been led out of South Asia and sub-Saharan Africa, the regions carrying the heaviest burden.

  1. 1999UNICEF, WHO, and United Nations University agree on the UNIMMAP formulation of 15 antenatal micronutrients
  2. 2000s-2010sLarge field trials across South Asia, sub-Saharan Africa, and elsewhere compare MMS with iron-folic acid
  3. 2017Individual-patient-data meta-analysis of 17 LMIC trials (Smith and colleagues) shows greater benefit for anemic and undernourished women
  4. 2019Cochrane review (Keats and colleagues) of 20 trials finds MMS reduces low birthweight versus iron-folic acid, rated high certainty
  5. 2020WHO updates antenatal guidance from advising against MMS to recommending it in the context of rigorous research
  6. 2020-2024The IMPROVING project introduces MMS through implementation research in Bangladesh, Burkina Faso, Madagascar, and Tanzania
  7. 2025IPD meta-analysis (Wang and colleagues) reports a 27 percent reduction in the highest-risk small-vulnerable-newborn type
  8. 2026Pragmatic cluster trial in ~83,798 Ethiopian births confirms a small real-world birthweight gain under routine antenatal care

At a glance

Standard (much of world)
Iron-folic acid (IFA)
MMS contains
15+ micronutrients
vs IFA
Fewer low-birth-weight, small-for-age
WHO stance
Increasingly supportive

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Multiple Micronutrient Supplements. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources